Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity-Reference-Cited by-同舟云学术

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity

Published:2019-12 Issue: Volume:141 Page:247-255
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Spiegelberg Linda,van Hoof Stefan J.,Biemans Rianne,Lieuwes Natasja G.,Marcus Damiënne,Niemans Raymon,Theys Jan,Yaromina Ala,Lambin Philippe^ORCID,Verhaegen Frank^ORCID,Dubois Ludwig J.^ORCID

Funder

Worldwide Cancer Research

ERC

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference48 articles.

1. Cancer statistics, 2016;Siegel;Cancer J Clin,2016

2. Annual report to the nation on the status of cancer, 1975–2014, featuring survival;Jemal;J Natl Cancer Inst,2017

3. Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: a systematic review;Peerlings;Methods,2017

4. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial;Shapiro;Lancet Oncol,2015

5. Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer;Klaassen;Radiother Oncol,2015

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 18F-Fluoroazomycin Arabinoside (FAZA) PET/MR as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study;Tomography;2024-08-30

2. Characterisation of quantitative imaging biomarkers for inflammatory and fibrotic radiation-induced lung injuries using preclinical radiomics;Radiotherapy and Oncology;2024-03

3. AGENTES ANTINEOPLÁSICOS BIORREDUTÍVEIS: AVANÇOS E DESAFIOS APÓS 20 ANOS;Química Nova;2024

4. Overcoming radioresistance with the hypoxia-activated prodrug CP-506: A pre-clinical study of local tumour control probability;Radiotherapy and Oncology;2023-09

5. Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer;MATH BIOSCI ENG;2023